New Urine and Blood Markers for Acute Kidney Injury in Liver Transplant Patients
Withdrawn
- Conditions
- Renal Insufficiency, Acute
- Registration Number
- NCT00855127
- Lead Sponsor
- University of Colorado, Denver
- Brief Summary
The purpose of this study is to find new blood and urine tests that detect acute kidney injury earlier than our current blood tests in patients receiving a liver transplant.
- Detailed Description
Patients with end stage liver disease that receive a liver transplant will be studied to determine if novel serum and urine biomarkers (serum cystatin C, urine interleukin-18 \[IL-18\] and urine neutrophil gelatinase associated lipocalin \[NGAL\]) can predict the outcome measures listed above.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- First time liver transplant recipient
- Cadaveric or living donor livers
Read More
Exclusion Criteria
- Unconscious patients or patients who cannot give consent
- Pregnant women
- Prisoners
- Patients receiving dialysis before or during liver transplant operation
- Patients receiving simultaneous liver-kidney transplants
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Development of acute kidney injury as defined by a 50% increase in serum creatinine Within 2 to 5 days of liver transplant that is sustained for at least 24 hours
- Secondary Outcome Measures
Name Time Method The need for renal replacement therapy After liver transplant operation to discharge Development of severe acute kidney injury, as defined as a doubling of serum creatinine Within 2-5 days of transplant that is sustained for at least 24 hours All cause mortality After liver transplant operation to discharge
Trial Locations
- Locations (2)
University of Colorado Denver
🇺🇸Aurora, Colorado, United States
University of Washington
🇺🇸Seattle, Washington, United States